TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25459392

Group type: COMPARATOR
Intervention: Gemcitabine (GEM) at a dosage of 1.000mg/m² d1, 8, 15 q28
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus sunitinib (SUNGEM) with GEM 1.000mg/m² d1+8 and sunitinib 50mg p.o. d1-14, q21d
Number of subjects: 106

Group type: COMPARATOR
Intervention: Gemcitabine (GEM)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus sunitinib (SUNGEM)
Number of subjects: 106
Study: 23780899

Group type: EXPERIMENTAL
Intervention: Wetsuit worn out of water
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Wetsuit during immersion
Number of subjects: 8

Group type: COMPARATOR
Intervention: No wetsuit worn out of water (control)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Wetsuit scuba-immersed sessions at 1, 6 and 12 msw depth
Number of subjects: 8
Study: 21959870

Group type: EXPERIMENTAL
Intervention: Epoetin-β (EPO) 36,000 IU weekly for 12 weeks
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Epoetin-β (EPO) and Placebo
Number of subjects: 186
Study: 19567317

Group type: COMPARATOR
Intervention: Fluoride varnish
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (100 mJ, 20 Hz)
Number of subjects: 20
Study: 16489080

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/d
Number of subjects: 171

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/d
Number of subjects: 171
Study: 15369422

Group type: EXPERIMENTAL
Intervention: Physician Letter arm
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Physician/Member Letter arm
Number of subjects: 2614

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 2614

Group type: EXPERIMENTAL
Intervention: Financial modeling analysis
Number of subjects: 2614
Study: 11102251

Group type: EXPERIMENTAL
Intervention: Lanoteplase 120 KU/kg as a single intravenous bolus
Number of subjects: 15078

Group type: COMPARATOR
Intervention: Accelerated alteplase up to 100 mg given over 90 min
Number of subjects: 15078
Study: 9470884

Group type: EXPERIMENTAL
Intervention: Active nicotine patch (24 hour transdermal nicotine patch over a 10 week course)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo nicotine patch
Number of subjects: 305
Study: 7958544

Group type: EXPERIMENTAL
Intervention: Monomeric insulin analogue [Lys(B28),Pro(B29)] (MI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular human insulin (HI)
Number of subjects: 0
Study: 2884796

Group type: EXPERIMENTAL
Intervention: atracurium 0.5 mg X kg‐1
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: pipecuronium 0.1 mg X kg‐1
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: vecuronium 0.1 mg X kg‐1
Number of subjects: 34
Study: 29458408

Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Thoracoscopic Surgical Ablation
Number of subjects: 120
Study: 26563915

Group type: EXPERIMENTAL
Intervention: Vitamin D-containing supplements ≥3 days/week
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA) (min/d)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Outdoor walking during school hours (min/week)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Age (per year)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Sampling in October
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Sampling in November
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Non-white ethnicity
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Immigrant/descendant background
Number of subjects: 782
Study: 24670200

Group type: EXPERIMENTAL
Intervention: QualiCCare education for GPs
Number of subjects: 288

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 288
Study: 22388300

Group type: EXPERIMENTAL
Intervention: Bioactive stents (BAS)
Number of subjects: 425

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 425
Study: 20811077

Group type: EXPERIMENTAL
Intervention: Combined program (proprioception + GMS)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: GMS training
Number of subjects: 48

Group type: COMPARATOR
Intervention: Proprioception training
Number of subjects: 48
Study: 18193397

Group type: EXPERIMENTAL
Intervention: High-selenium yeast (300 microg/day)
Number of subjects: 42
Study: 15993459

Group type: EXPERIMENTAL
Intervention: Focused spatial attention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooling mechanism
Number of subjects: 0
Study: 12627405

Group type: EXPERIMENTAL
Intervention: Proposed treatment method based on joint toxicity and efficacy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual tests
Number of subjects: 0
Study: 9831781

Group type: EXPERIMENTAL
Intervention: Amine fluoride dentifrice (F = 1,250 ppm)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amine fluoride/sodium fluoride mouthrinse (total F = 250 ppm)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amine fluoride dentifrice alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amine fluoride dentifrice combined with fluoride mouthrinse
Number of subjects: 12
Study: 8644905

Group type: EXPERIMENTAL
Intervention: Praziquantel
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 1530022

Group type: EXPERIMENTAL
Intervention: Estrostep
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Loestrin
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 3921141

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 25
Study: 30220726

Group type: EXPERIMENTAL
Intervention: WEBB program (n=13)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Unilateral balance training (n=12)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 35
Study: 26643085

Group type: EXPERIMENTAL
Intervention: Zoledronic acid every 4 weeks for 12 weeks
Number of subjects: 73

Group type: COMPARATOR
Intervention: Pamidronate every 4 weeks for 12 weeks
Number of subjects: 73
Study: 25246489

Group type: EXPERIMENTAL
Intervention: Baclofen 30 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Baclofen 60 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 22540412

Group type: EXPERIMENTAL
Intervention: Platform-switched implants (mismatch 0.35-0.40 mm)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional implants (control)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups (test and control)
Number of subjects: 80
Study: 20730060

Group type: EXPERIMENTAL
Intervention: Valsartan 40 mg bid (n = 60)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg qd (n = 55)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Valsartan (both dosing regimens)
Number of subjects: 115
Study: 18680178

Group type: EXPERIMENTAL
Intervention: Nasal mask
Number of subjects: 20
Study: 16183682

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with fentanyl 3 microg ml(‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.125% with clonidine 0.6 microg ml(‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (bupivacaine alone, bupivacaine with fentanyl, bupivacaine with clonidine)
Number of subjects: 60
Study: 12861131

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (0.625 mg/d) plus medroxyprogesterone acetate (5 mg/d for 13 days every 3 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 10391093

Group type: EXPERIMENTAL
Intervention: GST alpha and pi immunostaining in normal squamous epithelium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GST alpha and pi immunostaining in Barrett's epithelium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GST alpha and pi immunostaining in adenocarcinoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GST alpha and pi immunostaining in squamous cell carcinoma
Number of subjects: 0
Study: 8873228

Group type: EXPERIMENTAL
Intervention: Nabumetone (1000 mg once daily)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Piroxicam (20 mg once daily)
Number of subjects: 198
Study: 1387806

Group type: COMPARATOR
Intervention: Piperacillin plus amikacin
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin plus teicoplanin
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin with teicoplanin after 72 hours
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Piperacillin plus amikacin plus amphotericin B after 72 hours
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Initial empirical regimen with antibiotics active against gram-positive organisms
Number of subjects: 158
Study: 7091512

Group type: EXPERIMENTAL
Intervention: Sympathectomy
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nonsympathectomy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 67
Study: 30113522

Group type: EXPERIMENTAL
Intervention: whey protein (25 g) plus HMB (1.5 g)
Number of subjects: 26

Group type: COMPARATOR
Intervention: whey protein (25 g) plus leucine (1.5 g)
Number of subjects: 26
Study: 30562371

Group type: EXPERIMENTAL
Intervention: African Descent (AD)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: European Descent (ED)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Mixed Descent (MD)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Overall comparison among groups
Number of subjects: 260
Study: 27223310

Group type: EXPERIMENTAL
Intervention: Decision Navigation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 56
Study: 24584876

Group type: EXPERIMENTAL
Intervention: Standard doxorubicin-cyclophosphamide followed by paclitaxel with bevacizumab therapy (duration not specified)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard doxorubicin-cyclophosphamide followed by paclitaxel with placebo
Number of subjects: 124
Study: 22965699

Group type: EXPERIMENTAL
Intervention: Western medicine combined with Chinese medicine (CM) treatment
Number of subjects: 125

Group type: COMPARATOR
Intervention: Western medicine (Amlodipine Besylate Tablets and Irbesartan Tablets or Irbesartan and Hydrochlorothiazide Tablets)
Number of subjects: 125
Study: 19575284

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil (CEF)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 294
Study: 18845709

Group type: EXPERIMENTAL
Intervention: Single PS dose consumed as an afternoon snack (1.6 g/d)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Single PS dose consumed with a meal (1.6 g/d)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control phase
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Single PS dose consumed as an afternoon snack
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Single PS dose consumed with a meal
Number of subjects: 26
Study: 16150741

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention (diagnostic and treatment algorithm, small group sessions, videotapes, written material, outreach visits, one-on-one interviews with physicians)
Number of subjects: 4217

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4217

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 4217
Study: 12393997

Group type: EXPERIMENTAL
Intervention: CNF (cyclophosphamide, mitoxantrone, 5-fluorouracil)
Number of subjects: 145

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, 5-fluorouracil)
Number of subjects: 145
Study: 10202165

Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m² per week for six weeks (group 1)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m² on days 1 and 29, 4 g of fluorouracil per m² as a 96-hour infusion on days 1 and 29, and 2 g of oral hydroxyurea twice weekly for six weeks (group 2)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Hydroxyurea 3 g/m² twice weekly for six weeks (group 3)
Number of subjects: 526
Study: 7869476

Group type: EXPERIMENTAL
Intervention: Indoramin (alpha 1‐adrenergic receptor antagonist)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2611090

Group type: EXPERIMENTAL
Intervention: Aspirin 1.95 g day‐1 for 1 week
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aspirin 3.25 g day‐1 for 1 week
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aspirin 4.55 g day‐1 for 1 week
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Aspirin 5.85 g day‐1 for 1 week
Number of subjects: 8
Study: 30703643

Group type: EXPERIMENTAL
Intervention: Forefoot landing (FFOOT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Forward trunk lean (FTL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10% step rate increase (SR10%)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Gait retraining (all groups)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: FFOOT
Number of subjects: 18
Study: 28301035

Group type: EXPERIMENTAL
Intervention: Educative group (EG)
Number of subjects: 775

Group type: COMPARATOR
Intervention: Comparative group (CG)
Number of subjects: 775

Group type: EXPERIMENTAL
Intervention: Behavioral group (BG)
Number of subjects: 775
Study: 25451428

Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention (PFI) and Treatment As Usual (TAU)
Number of subjects: 137

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Psychoeducational family intervention (PFI)
Number of subjects: 137
Study: 23553151

Group type: EXPERIMENTAL
Intervention: Flavonoid-enriched chocolate (27 g/d; 850 mg flavan-3-ols + 100 mg isoflavones)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Flavonoid-enriched chocolate
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 22162988

Group type: EXPERIMENTAL
Intervention: Strategy A (two standard doses over 28 days)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Strategy B (two double doses over 28 days)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Strategy C (single standard dose of influenza vaccine)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Strategy D (previous year's standard-dose vaccination)
Number of subjects: 298
Study: 18085694

Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg/day
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 71
Study: 16282339

Group type: EXPERIMENTAL
Intervention: Acyclovir 800 mg twice daily
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Acyclovir
Number of subjects: 77
Study: 12907205

Group type: EXPERIMENTAL
Intervention: High SES index
Number of subjects: 47800

Group type: EXPERIMENTAL
Intervention: Higher education levels
Number of subjects: 47800

Group type: EXPERIMENTAL
Intervention: Higher income
Number of subjects: 47800

Group type: EXPERIMENTAL
Intervention: SES factors (education, occupation, income)
Number of subjects: 47800
Study: 10922130

Group type: EXPERIMENTAL
Intervention: Prednisolone 1 mg/kg/day for 7 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 8731624

Group type: EXPERIMENTAL
Intervention: Self-management plans issued by general practitioners to patients with asthma
Number of subjects: 906

Group type: COMPARATOR
Intervention: Control group (no self-management plans)
Number of subjects: 906
Study: 1329618

Group type: EXPERIMENTAL
Intervention: Rufloxacin 400 mg loading dose followed by 200 mg daily for 9 days
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Rufloxacin 600 mg loading dose followed by 300 mg daily for 9 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 4019262

Group type: EXPERIMENTAL
Intervention: Riboflavin plus iron supplements
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Iron supplements
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 31599341

Group type: EXPERIMENTAL
Intervention: Prior radiotherapy (RT)
Number of subjects: 1825

Group type: EXPERIMENTAL
Intervention: Having breast cancer
Number of subjects: 1825

Group type: EXPERIMENTAL
Intervention: Previous RT plus having breast cancer
Number of subjects: 1825
Study: 30045595

Group type: EXPERIMENTAL
Intervention: Posterolateral fusion (PLF)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Posterior lumbar interbody fusion (PLIF)
Number of subjects: 88
Study: 27365262

Group type: EXPERIMENTAL
Intervention: STOPP/START criteria intervention
Number of subjects: 732

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 732
Study: 24112670

Group type: EXPERIMENTAL
Intervention: Ketorolac
Number of subjects: 619

Group type: COMPARATOR
Intervention: Control (no ketorolac)
Number of subjects: 619
Study: 22487155

Group type: EXPERIMENTAL
Intervention: Interval training combined with thigh cuffs pressure of +90 mmHg (CUFF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups (CUFF and CON)
Number of subjects: 20
Study: 20660803

Group type: EXPERIMENTAL
Intervention: Autopsy findings in patients classified as sudden death events
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Time after myocardial infarction
Number of subjects: 105
Study: 17965424

Group type: EXPERIMENTAL
Intervention: etoricoxib 90 mg daily
Number of subjects: 4086

Group type: COMPARATOR
Intervention: diclofenac 75 mg twice daily
Number of subjects: 4086
Study: 16195291

Group type: EXPERIMENTAL
Intervention: Various interventions for prevention (42 trials)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Various interventions for treatment (35 trials)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Funding sources
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Power calculations
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ethical considerations
Number of subjects: 77
Study: 11849795

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Nonirradiated
Number of subjects: 103
Study: 10190667

Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline infusion
Number of subjects: 164

Group type: COMPARATOR
Intervention: Extra-amniotic prostaglandin F2alpha
Number of subjects: 164
Study: 7674172

Group type: EXPERIMENTAL
Intervention: Poly(methyl methacrylate) intraocular lens
Number of subjects: 59

Group type: COMPARATOR
Intervention: Heparin-surface-modified lens
Number of subjects: 59
Study: 2403065

Group type: EXPERIMENTAL
Intervention: Caffeine (400 mg/d)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (identical-appearing placebos with decaffeinated coffee)
Number of subjects: 16
Study: 7223262

Group type: EXPERIMENTAL
Intervention: Cefamandole (3 x 2 g I.V. within 24 hrs, first dose at anesthetic induction)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clindamycin-Tobramycin (clindamycin 600 mg - tobramycin 80 mg/8 hrs for 24 hrs, first dose at anesthetic induction)
Number of subjects: 100
Study: 31702714

Group type: EXPERIMENTAL
Intervention: Phacoemulsification
Number of subjects: 79

Group type: COMPARATOR
Intervention: Phacotrabeculectomy
Number of subjects: 79
Study: 31293021

Group type: EXPERIMENTAL
Intervention: N. sativa (2 g/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 28360223

Group type: EXPERIMENTAL
Intervention: CT screening (baseline, 1 year, 2 years, 2.5 years)
Number of subjects: 7900
Study: 26087864

Group type: EXPERIMENTAL
Intervention: 0.15% ethyl lauroyl arginate (LAE)-containing mouthrinse
Number of subjects: 87

Group type: COMPARATOR
Intervention: 5% hydroalcohol-negative control
Number of subjects: 87
Study: 23955585

Group type: COMPARATOR
Intervention: FOLFIRI + FOLFOX4
Number of subjects: 125

Group type: COMPARATOR
Intervention: FOLFIRI‐HD
Number of subjects: 125

Group type: COMPARATOR
Intervention: FOLFOX7
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control arms (standard chemotherapy)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Experimental arms (intensified chemotherapy)
Number of subjects: 125
Study: 21565324

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 19446622

Group type: EXPERIMENTAL
Intervention: PHFST 240 mg single dose
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: PHFST 180-210 mg single dose
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: PHFST 30-150 mg single dose
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: PHFST multiple dosing (60 mg b.i.d. up to 120 mg b.i.d.)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: PHFST
Number of subjects: 116
Study: 16519093

Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 29
Study: 11861338

Group type: EXPERIMENTAL
Intervention: Pulmonary artery catheter (PAC) use in low-risk patients undergoing CABG and AAR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 10373727

Group type: EXPERIMENTAL
Intervention: Daytime mechanical ventilation (DV)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Nocturnal mechanical ventilation (NV)
Number of subjects: 34
Study: 8562752

Group type: EXPERIMENTAL
Intervention: 1 g of azithromycin orally (single dose)
Number of subjects: 133

Group type: COMPARATOR
Intervention: 250 mg of ceftriaxone im (single dose)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Both azithromycin and ceftriaxone
Number of subjects: 133
Study: 2248071

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 63

Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 63
Study: 6101535

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Exposure in vivo
Number of subjects: 76

Group type: COMPARATOR
Intervention: Imaginal desensitization
Number of subjects: 76